10x Genomics shares fall 1.26% intraday despite launching Xenium Protein, a new spatial multiomic assay.

10x Genomics, Inc. declined 1.26% in intraday trading, despite the company launching Xenium Protein, a new addition to its Xenium Spatial platform that enables simultaneous RNA and protein detection in the same cell, on the same tissue section, all in a single automated run. This advancement brings RNA and protein data together in situ, unlocking deeper insights into cell function and disease biology.